A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
Phase 3
Completed
- Conditions
- Hyperhidrosis
- Registration Number
- NCT00168402
- Lead Sponsor
- Allergan
- Brief Summary
This is a three-year study in subjects with axillary hyperhidrosis involving injection of Botulinum Toxin Type A into the axilla to reduce sweating.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 193
Inclusion Criteria
- Marked axillary hyperhidrosis
Exclusion Criteria
- Previous use of botulinum toxin for hyperhidrosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Subject's assessment of the severity of hyperhidrosis
- Secondary Outcome Measures
Name Time Method Measurement of axillary sweat production
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which Botulinum Toxin Type A inhibits sweat gland activity in axillary hyperhidrosis?
How does Botulinum Toxin Type A compare to anticholinergic medications in treating axillary hyperhidrosis?
Are there specific biomarkers that correlate with long-term efficacy of Botulinum Toxin Type A in hyperhidrosis patients?
What are the most common adverse events associated with Botulinum Toxin Type A injections for axillary hyperhidrosis and their management?
What are the current developments in neuromodulator therapies for focal hyperhidrosis beyond Botulinum Toxin Type A?